Cardioprotection afforded by NF-κB ablation is associated with activation of Akt in mice overexpressing TNF-α

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 290, Issue 2, 2006, Pages

  Higuchi, Yoshihiro ^a   Chan, Tung O ^a   Brown, Maria A ^b   Zhang, Jin ^a   DeGeorge Jr , Brent R ^a   Funakoshi, Hajime ^a   Gibson, Gregory ^c   McTiernan, Charles F ^c   Kubota, Toru ^d   Jones, W Keith ^b   Feldman, Arthur M ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d KYUSHU UNIVERSITY   (Japan)

Author keywords

Dominant negative inhibitory B protein transgene; Insulin signaling; Protein kinase B; TNF receptor; Tumor necrosis factor

Indexed keywords

CYTOKINE; PROTEIN KINASE B; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR 1; CARDIOTONIC AGENT; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOMYOPATHY; CONTROLLED STUDY; ECHOCARDIOGRAPHY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL MODEL; GENE ACTIVATION; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; MOUSE; NONHUMAN; PHOSPHORYLATION; PRIORITY JOURNAL; STATISTICAL ANALYSIS; SURVIVAL; TRANSGENE; ANIMAL; DOMINANT GENE; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; MALE; METABOLISM; MOUSE MUTANT; TRANSGENIC MOUSE;

ANIMALS; CARDIOTONIC AGENTS; GENES, DOMINANT; I-KAPPA B PROTEINS; INSULIN; MALE; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; NF-KAPPA B; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33644859066     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00379.2005     Document Type: Article

References (46)

1. Ananthakrishnan R, Moe GW, Goldenthal MJ, and Marin-Garcia J. Akt signaling pathway in pacing-induced heart failure. Mol Cell Biochem 268: 103-110, 2005.
2. Baldwin AS Jr. The NF-κB and IκB proteins: new discoveries and insights. Annu Rev Immunol 14: 649-683, 1996.
3. Baldwin AS Jr. Series introduction: the transcription factor NF-κB and human disease. J Clin Invest 107: 3-6, 2001.
4. Bergmann MW, Loser P, Dietz R, and von Harsdorf R. Effect of NF-κB inhibition on TNF-α-induced apoptosis and downstream pathways in cardiomyocytes. J Mol Cell Cardiol 33: 1223-1232, 2001.
5. Brancaccio M, Fratta L, Notte A, Hirsch E, Poulet R, Guazzone S, De Acetis M, Vecchione C, Marino G, Altruda F, Silengo L, Tarone G, and Lembo G. Melusin, a muscle-specific integrin β1-interacting protein, is required to prevent cardiac failure in response to chronic pressure overload. Nat Med 9: 68-75, 2003.
6. Brazil DP, Yang ZZ, and Hemmings BA. Advances in protein kinase B signalling: AKTion on multiple fronts. Trends Biochem Sci 29: 233-242, 2004.
7. Brown MA, McGuinness M, Wright T, Ren X, Wang Y, Boivin GP, Hahn H, Feldman AM, and Jones WK. Cardiac-specific blockade of NF-κB in cardiac pathophysiology: differences between acute and chronic stimuli in vivo. Am J Physiol Heart Circ Physiol 289: H466-H476, 2005.
8. Chan TO, Rodeck U, Chan AM, Kimmelman AC, Rittenhouse SE, Panayotou G, and Tsichlis PN. Small GTPases and tyrosine kinases coregulate a molecular switch in the phosphoinositide 3-kinase regulatory subunit. Cancer Cell 1: 181-191, 2002.
9. Cho H, Mu J, Kim JK, Thorvaldsen JL, Chu Q, Crenshaw EB III, Kaestner KH, Bartolomei MS, Shulman GI, and Birnbaum MJ. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB β). Science 292: 1728-1731, 2001.
10. Cho H, Thorvaldsen JL, Chu Q, Feng F, and Birnbaum MJ. Akt1/PKBα is required for normal growth but dispensable for maintenance of glucose homeostasis in mice. J Biol Chem 276: 38349-38352, 2001.
11. Condorelli G, Drusco A, Stassi G, Bellacosa A, Roncarati R, Iaccarino G, Russo MA, Gu Y, Dalton N, Chung C, Latronico MV, Napoli C, Sadoshima J, Croce CM, and Ross J Jr. Akt induces enhanced myocardial contractility and cell size in vivo in transgenic mice. Proc Natl Acad Sci USA 99: 12333-12338, 2002.
12. Condorelli G, Morisco C, Latronico MV, Claudio PP, Dent P, Tsichlis P, Frati G, Drusco A, Croce CM, and Napoli C. TNF-α signal transduction in rat neonatal cardiac myocytes: definition of pathways generating from the TNF-α receptor. FASEB J 16: 1732-1737, 2002.
13. Dawn B, Xuan YT, Marian M, Flaherty MP, Murphree SS, Smith TL, Bolli R, and Jones WK. Cardiac-specific abrogation of NF-κB activation in mice by transdominant expression of a mutant IκB-α. J Mol Cell Cardiol 33: 161-173, 2001.
14. Feldman AM, Combes A, Wagner D, Kadakomi T, Kubota T, Li YY, and McTiernan C. The role of tumor necrosis factor in the pathophysiology of heart failure. J Am Coll Cardiol 35: 537-544, 2000.
15. Fujio Y, Nguyen T, Wencker D, Kitsis RN, and Walsh K. Akt promotes survival of cardiomyocytes in vitro and protects against ischemia-reperfusion injury in mouse heart. Circulation 101: 660-667, 2000.
16. Gustin JA, Ozes ON, Akca H, Pincheira R, Mayo LD, Li Q, Guzman JR, Korgaonkar CK, and Donner DB. Cell type-specific expression of the IκB kinases determines the significance of phosphatidylinositol 3-kinase/Akt signaling to NF-κB activation. J Biol Chem 279: 1615-1620, 2004.
17. Hanada M, Feng J, and Hemmings BA. Structure, regulation and function of PKB/AKT - a major therapeutic target. Biochim Biophys Acta 1697: 3-16, 2004.
18. Higuchi Y, McTiernan CF, Frye CB, McGowan BS, Chan TO, and Feldman AM. Tumor necrosis factor receptors 1 and 2 differentially regulate survival, cardiac dysfunction, and remodeling in transgenic mice with tumor necrosis factor-α-induced cardiomyopathy. Circulation 109: 1892-1897, 2004.
19. Hoffmann A, Levchenko A, Scott ML, and Baltimore D. The IκB-NF-κB signaling module: temporal control and selective gene activation. Science 298: 1241-1245, 2002.
20. Jones WK, Brown M, Wilhide M, He S, and Ren X. NF-κB in cardiovascular disease: diverse and specific effects of a "general" transcription factor? Cardiovasc Toxicol 5: 183-202, 2005.
21. Kadokami T, Frye C, Lemster B, Wagner CL, Feldman AM, and McTiernan CF. Anti-tumor necrosis factor-α antibody limits heart failure in a transgenic model. Circulation 104: 1094-1097, 2001.
22. Kawamura N, Kubota T, Kawano S, Monden Y, Feldman AM, Tsutsui H, Takeshita A, and Sunagawa K. Blockade of NF-κB improves cardiac function and survival without affecting inflammation in TNF-α-induced cardiomyopathy. Cardiovasc Res 66: 520-529, 2005.
23. Krikos A, Laherty CD, and Dixit VM. Transcriptional activation of the tumor necrosis factor-α-inducible zinc finger protein, A20, is mediated by κB elements. J Biol Chem 267: 17971-17976, 1992.
24. Kubota T, McTiernan CF, Frye CS, Slawson SE, Lemster BH, Koretsky AP, Demetris AJ, and Feldman AM. Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-α. Circ Res 81: 627-635, 1997.
25. Kubota T, Miyagishima M, Frye CS, Alber SM, Bounoutas GS, Kadokami T, Watkins SC, McTiernan CF, and Feldman AM. Overexpression of tumor necrosis factor-α activates both anti- and pro-apoptotic pathways in the myocardium. J Mol Cell Cardiol 33: 1331-1344, 2001.
26. Machida Y, Kubota T, Kawamura N, Funakoshi H, Ide T, Utsumi H, Li YY, Feldman AM, Tsutsui H, Shimokawa H, and Takeshita A. Overexpression of tumor necrosis factor-α increases production of hydroxyl radical in murine myocardium. Am J Physiol Heart Circ Physiol 284: H449-H455, 2003.
27. Madrid LV, Mayo MW, Reuther JY, and Baldwin AS Jr. Akt stimulates the transactivation potential of the RelA/p65 subunit of NF-κB through utilization of the IκB kinase and activation of the mitogen-activated protein kinase p38. J Biol Chem 276: 18934-18940, 2001.
28. Matsui T, Li L, Wu JC, Cook SA, Nagoshi T, Picard MH, Liao R, and Rosenzweig A. Phenotypic spectrum caused by transgenic overexpression of activated Akt in the heart. J Biol Chem 277: 22896-22901, 2002.
29. Matsui T and Rosenzweig A. Convergent signal transduction pathways controlling cardiomyocyte survival and function: the role of PI 3-kinase and Akt. J Mol Cell Cardiol 38: 63-71, 2005.
30. Matsui T, Tao J, del Monte F, Lee KH, Li L, Picard M, Force TL, Franke TF, Hajjar RJ, and Rosenzweig A. Akt activation preserves cardiac function and prevents injury after transient cardiac ischemia in vivo. Circulation 104: 330-335, 2001.
31. Maulik N, Sasaki H, Addya S, and Das DK. Regulation of cardiomyocyte apoptosis by redox-sensitive transcription factors. FEBS Lett 485: 7-12, 2000.
32. McMullen JR, Shioi T, Zhang L, Tarnavski O, Sherwood MC, Kang PM, and Izumo S. Phosphoinositide 3-kinase(p110α) plays a critical role for the induction of physiological, but not pathological, cardiac hypertrophy. Proc Natl Acad Sci USA 100: 12355-12360, 2003.
33. Misra A, Haudek SB, Knuefermann P, Vallejo JG, Chen ZJ, Michael LH, Sivasubramanian N, Olson EN, Entman ML, and Mann DL. Nuclear factor-κB protects the adult cardiac myocyte against ischemiainduced apoptosis in a murine model of acute myocardial infarction. Circulation 108: 3075-3078, 2003.
34. Moe GW and Armstrong P. Pacing-induced heart failure: a model to study the mechanism of disease progression and novel therapy in heart failure. Cardiovasc Res 42: 591-599, 1999.
35. Moe GW, Marin-Garcia J, Konig A, Goldenthal M, Lu X, and Feng Q. In vivo TNF-alpha inhibition ameliorates cardiac mitochondrial dysfunction, oxidative stress, and apoptosis in experimental heart failure. Am J Physiol Heart Circ Physiol 287: H1813-H1820, 2004.
36. Olson EN. A decade of discoveries in cardiac biology. Nat Med 10: 467-474, 2004.
37. Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, and Donner DB. NF-κB activation by tumour necrosis factor requires the Akt serinethreonine kinase. Nature 401: 82-85, 1999.
38. Park S, Higashimori T, Barger P, Mann D, and Kim J. Mice with heart-specific overexpression of TNF develop cardiac insulin resistance. Circulation 110: III-127, 2004.
39. Shioi T, Kang PM, Douglas PS, Hampe J, Yballe CM, Lawitts J, Cantley LC, and Izumo S. The conserved phosphoinositide 3-kinase pathway determines heart size in mice. EMBO J 19: 2537-2548, 2000.
40. Shioi T, McMullen JR, Kang PM, Douglas PS, Obata T, Franke TF, Cantley LC, and Izumo S. Akt/protein kinase B promotes organ growth in transgenic mice. Mol Cell Biol 22: 2799-2809, 2002.
41. Shiraishi I, Melendez J, Ahn Y, Skavdahl M, Murphy E, Welch S, Schaefer E, Walsh K, Rosenzweig A, Torella D, Nurzynska D, Kajstura J, Leri A, Anversa P, and Sussman MA. Nuclear targeting of Akt enhances kinase activity and survival of cardiomyocytes. Circ Res 94: 884-891, 2004.
42. Sugden PH. Ras, Akt, and mechanotransduction in the cardiac myocyte. Circ Res 93: 1179-1192, 2003.
43. Taniyama Y and Walsh K. Elevated myocardial Akt signaling ameliorates doxorubicin-induced congestive heart failure and promotes heart growth. J Mol Cell Cardiol 34: 1241-1247, 2002.
44. Tian B, Nowak DE, Jamaluddin M, Wang S, and Brasier AR. Identification of direct genomic targets downstream of the NF-κB transcription factor mediating TNF signaling. J Biol Chem 280: 17435-17448, 2005.
45. Wisniacki N, Taylor W, Lye M, and Wilding JP. Insulin resistance and inflammatory activation in older patients with systolic and diastolic heart failure. Heart 91: 32-37, 2005.
46. Zhang J, Ping P, Vondriska TM, Tang XL, Wang GW, Cardwell EM, and Bolli R. Cardioprotection involves activation of NF-κB via PKC-dependent tyrosine and serine phosphorylation of IκB-α. Am J Physiol Heart Circ Physiol 285: H1753-H1758, 2003.